This year in review of 2025 milestones in idiopathic pulmonary fibrosis (IPF) features coverage of research on therapeutic efficacy presented at the American Thoracic Society 2025 International Conference in May, as well as studies on lung function thresholds and mortality predictors. It also includes interviews with Marilyn Glassberg, MD, on the significance of early diagnosis of IPF, and Justin M. Oldham, MD, PhD, MS, on first-line treatment choices for the chronic lung disease.
